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The susceptibility gene for ataxia telangiectasia, ATM, is also an intermediate-risk breast-cancer-susceptibility gene. However, the spec-
trum and frequency distribution of ATM mutations that confer increased risk of breast cancer have been controversial. To assess the
contribution of rare variants in this gene to risk of breast cancer, we pooled data from seven published ATM case-control mutation-
screening studies, including a total of 1544 breast cancer cases and 1224 controls, with data from our own mutation screening of an
additional 987 breast cancer cases and 1021 controls. Using an in silico missense-substitution analysis that provides a ranking of
missense substitutions from evolutionarily most likely to least likely, we carried out analyses of protein-truncating variants, splice-junc-
tion variants, and rare missense variants. We foundmarginal evidence that the combination of ATM protein-truncating and splice-junc-
tion variants contribute to breast cancer risk. There was stronger evidence that a subset of rare, evolutionarily unlikely missense substi-
tutions confer increased risk. On the basis of subset analyses, we hypothesize that rare missense substitutions falling in and around the
FAT, kinase, and FATC domains of the protein may be disproportionately responsible for that risk and that a subset of these may confer
higher risk than do protein-truncating variants. We conclude that a comparison between the graded distributions of missense substitu-
tions in cases versus controls can complement analyses of truncating variants and help identify susceptibility genes and that this
approach will aid interpretation of the data emerging from new sequencing technologies.Introduction
The susceptibility gene for the autosomal-recessive
disorder ataxia telangiectasia (A-T [MIM 208900]), ATM
(MIM 607585), encodes a protein of 3056 amino acids
that is activated in response to DNA damage and phos-
phorylates proteins involved in DNA repair and cell-cycle
control.1–3 Before ATM was identiﬁed, investigation of
the family histories of A-T patients revealed that heterozy-
gous mutation carriers are at increased risk of cancer,
particularly breast cancer.4 After the cloning of ATM,
several investigators conductedmutation screening studies
intended to clarify the role of ATM sequence variation in
breast cancer risk. The results were controversial; some
found evidence that truncating mutations in ATM were
important, others found that missense substitutions were
important, and others found little evidence of associated
risk.5–13
Recently, Renwick et al. mutation-screened ATM in
a series of familial breast cancer cases and ethnically similarThe Amercontrols and then compared the summed frequency of
clearly pathogenic (for A-T) sequence variants in cases
versus controls.14 Their results conﬁrmed that ATM is an
intermediate-risk breast cancer susceptibility gene: inheri-
tance of variants that are clearly pathogenic for A-T confers
increased risk of breast cancer with an odds ratio (OR) of 2
to 3, which is between the ORs conferred by high-risk vari-
ants in BRCA1 (MIM 113705) and BRCA2 (MIM 600185)
and those due to common modest-risk SNPs in genes
such as FGFR2 (MIM 176943) and TOX3 (alias TNRC9
[MIM 611416]).15,16 However, the combined bioinformatic
and statistical analysis model employed by Renwick et al.
was not sufﬁciently powerful to compare the relative
contribution of protein-truncating variants and missense
substitutions to the burden of breast cancer attributable
to sequence variation in ATM.
To improve the power of case-control mutation-
screening studies, we developed an analysis strategy to esti-
mate risk attributable to rare missense substitutions in
a known or candidate susceptibility gene.17 The analysis1International Agency for Research on Cancer, 69372 Lyon, France; 2Institute of Functional Genomics, University of Regensburg, 93053 Regensburg,
Germany; 3Queensland Institute of Medical Research, Brisbane, QLD 4029, Australia; 4Institut Curie - Recherche; INSERM U612; 91405 Orsay, France;
5Department of Biomedical Informatics, University of Utah School of Medicine, Salt Lake City, UT 84112, USA; 6Peter MacCallum Cancer Centre, Mel-
bourne, VIC 3002, Australia; 7Research Division, National Cancer Institute, Bangkok 10400, Thailand; 8Centre for MEGA Epidemiology, University of Mel-
bourne, Carlton, VIC 3010, Australia; 9Cancer Care Ontario, Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai
Hospital, Toronto, ON, M5G 1X5 Canada; 10Northern California Cancer Center, Fremont, CA 94538, USA; 11Department of Health Research and Policy,
Stanford University School of Medicine, Stanford, CA 94305-5405, USA
12These authors contributed equally to this work
*Correspondence: georgia.trench@qimr.edu.au
DOI 10.1016/j.ajhg.2009.08.018. ª2009 by The American Society of Human Genetics. All rights reserved.ican Journal of Human Genetics 85, 427–446, October 9, 2009 427
strategy involves two main steps. In the ﬁrst step, evolu-
tionarily unlikely missense substitutions are resolved
from evolutionarily more likely missense substitutions
along a graded trend. In the second step, the case and
control distributions of graded missense substitutions are
compared with a one degree of freedom (DF) test for log-
linear trend. The strategy requires substantially complete
mutation screening of the gene of interest in a suitably
ascertained set of cases and controls and a protein multiple
sequence alignment of sufﬁcient phylogenetic depth to
enable robust grading of the missense substitutions. Appli-
cation of the strategy implies testing a null hypothesis
that has three components: (1) the gene harbors missense
substitutions that are pathogenic with respect to the
disease of interest, (2) the probability that a missense
substitution in the gene is pathogenic is directly associated
with the probability that it is evolutionarily deleterious,
and (3) the missense-substitution grading is directly associ-
ated with the probability that a missense substitution is
evolutionarily deleterious. Should any of these three
components be false, the data will show only random
association between case-control status and missense-
substitution grading: a signiﬁcant p value therefore implies
acceptance of all three components and rejection of the
corresponding null hypothesis.
Here, we apply our analysis strategy to ATM mutation
screening data pooled from seven published ATM case-
control mutation-screening studies, including a total of
1544 breast cancer cases and 1224 controls, plus data
from our own mutation screening of an additional 987
breast cancer cases and 1021 controls. We examine the
results from twoperspectives: the role of rareATM sequence
variants in risk of breast cancer and the contribution that
analyses of rare missense substitutions can make to future,
large-scale, case-control mutation-screening studies.
Subjects and Methods
Identiﬁcation of Studies Included
in the Meta-Analysis
To retrieve ATM mutation-screening data from the literature, we
searched PubMed, Web of Science, and EMBASE databases, using
the keywords [‘‘ATM’’], [‘‘breast cancer’’ or ‘‘breast neoplasm’’ or
‘‘breast carcinoma’’], and [‘‘mutation’’ or ’’polymorphism’’] for
reports up to January 2009. For our main analyses, we required
that the studies reported substantially complete mutation
screening of ATM in breast cancer cases and controls. Mutation-
screening results from case-only or control-only studies were
used as supplements to the main analyses. Several of the muta-
tion-screening papers included in themeta-analysis supplemented
their mutation screening with speciﬁc variant genotyping; we
excluded these data. Papers were excluded for any of the following
reasons: if patient ascertainment was on a phenotype other than
breast cancer (i.e., Hodgkin disease before breast cancer,18 familial
cancer in general,19 or breast plus breast-ovarian families in
a format in which it was not possible to determine which variant
was observed in which type of proband20); if patient selection was
based on a speciﬁc tumor phenotype (i.e., breast cancer cases428 The American Journal of Human Genetics 85, 427–446, Octobeselected because their tumors showed LOH at 11q2321 or speciﬁc
selection for early-stage breast tumors22); or if patients were specif-
ically selected because of a radiotherapy complication or because
of absence of a radiotherapy adverse reaction.23–25 There were
several instances of overlap in breast cancer cases between muta-
tion-screening studies. In these instances, the largest study
(usually, the most recent one) was included in the meta-analysis.
Consequently, several redundant studies26–29 were excluded.
Discrepancies in nucleotide designation versus amino acid desig-
nation were checked with relevant authors, and their responses
were used for correction of our data set.
ATM Sequences, Alignments,
and Missense-Substitution Analysis
We constructed an ATM protein multiple sequence alignment
that satisﬁed three criteria: (1) the individual sequences are
full-length and encode proteins that appear to be structurally
similar to human ATM from beginning to end, (2) the individual
sequences are substantially free of cDNA (or gene model) struc-
tural errors, and (3) the alignment contains an average of at least
three amino acid substitutions per position and meets the
missense-substitution-analysis program Sorting Intolerant From
Tolerant (SIFT) ‘‘median sequence conservation’’ criterion for
conﬁdent prediction of substitutions that should ‘‘affect protein
function.’’30
The alignment contained full-length sequences from human
(Homo sapiens), mouse (Mus musculus), pig (Sus scrofa), opossum
(Monodelphis domestica), chicken (Gallus gallus), frog (Xenopus lae-
vis), zebraﬁsh (Danio rerio), lancelet (Branchiostoma ﬂoridae), and
sea urchin (Strongylocentrotus purpuratus). Human (AAB65827.1),
mouse (NP_031525.2), pig (AAT01608.2), chicken (XP_417160.2),
frog (AAT72929.1), and partial zebraﬁsh (BAD91491.1) ATM
sequences were obtained from GenBank. To obtain ATM coding
sequences fromopossum, lancelet, andseaurchin,weusedacombi-
nation of tBLASTn31 and splice-junction prediction to build initial
gene models from the available genomic sequences.
In the case of the opossum sequence, two apparent anomalies in
the genomic sequence interfered with assembly of a gene model
matching the exonic structure of the other mammalian ATM
sequences. In addressing these anomalies, cDNA was prepared
from tissue samples of one gray short-tailed opossum (kindly
provided by Paul B. Samollow), PCR ampliﬁed across the region
of interest, and sequenced. After the resulting reﬁnements were
incorporated into the gene model, there remained four small
differences between our opossumATM predicted peptide sequence
and that of Ensemble (ENSMODP00000018290), but these did not
inﬂuence scoring of the human missense substitutions analyzed
here.
Because the lancelet and sea urchin ATM sequences are much
further diverged from mammalian ATM, there were many
uncertain areas in our initial gene models. Accordingly, we PCR
ampliﬁed their entire coding sequences from cDNA prepared
from one lancelet and one sea urchin (kindly provided by Michael
Schubert and R. Andrew Cameron, respectively) and sequenced
them.
We then used the MCoffee alignment suite32 to build an initial
protein multiple sequence alignment. The alignment was checked
for anomalies, particularly near the splice junctions, that might be
attributed to structural faults in the cDNA sequences rather than
to sequence divergence. When such anomalies were found in
one of the GenBank cDNA sequences, the corresponding genomic
sequence was checked and, if gene prediction from the genomicr 9, 2009
Table 1. ATM and Ortholog Sequence Accession Numbers and Cross-Species Sequence Comparisons
Organism
Accession
Number
GenBank
cDNA (%)a
Gene
Model (%)b
Confirmation
by Sequencing
(%)c
Pairwise Amino Acid Sequence Identity (%)d
Hs Mm Ss Md Gg Xl Dr Bf
Homo sapiens AAB65827.1 100.0 0.0 0.0
Mus musculus NP_031525.2 100.0 0.0 0.0 84.1
Sus scrofa AAT01608.1 100.0 0.0 0.0 88.4 82.6
Monodelphis
domestica
ACG68567.1,
ACG68568.1
0.0 88.7e 11.3 80.7 76.2 78.9
Gallus gallus XP_417160.2 0.0 99.7 þ 0.3f 0.0 69.5 66.7 68.5 70.5
Xenopus laevis AAT72929.1 100.0 0.0 64.5 62.7 63.6 65.9 64.6
Danio rerio BAD91491.1
ACJ03990.1
89.4 0.3f 10.6 54.2 53.2 53.4 53.9 53.4 54.3
Branchiostoma
ﬂoridae
ACG68443.1 0.0 0.0 100.0 36.9 36.3 36.6 36.5 37.2 37.7 36.6
Strongylocentrotus
purpuratus
ABY60856.1 0.0 0.0 100.0 34.8 34.6 34.7 35.0 35.9 35.3 35.2 38.1
a This is the percentage of the ATM amino acid sequence used in our alignment that was obtained directly from a GenBank cDNA entry.
b This is the percentage of the ATM amino acid sequence used in our alignment that was obtained by gene prediction.
c This is the percentage of the ATM amino acid sequence used in our alignment that we confirmed by RT-PCR and sequencing from model-organism cDNA.
d The two-letter species-name abbreviations are as follows: Hs, Homo sapiens; Mm, Mus musculus; Ss, Sus scrofa; Md, Monodelphis domestica; Gg, Gallus gallus; Xl,
Xenopus laevis; Dr, Danio rerio; Bf, Branchiostoma floridae. Note that the cross-comparison does not require a column for Strongylocentrotus purpuratus.
e Gene model built at IARC, but similar to Ensemble prediction ENSMODP00000018290.
f Corrections to apparent anomalies in a gene-model prediction obtained from GenBank, made by reference to the genomic sequence.sequence resulted in a better alignment than had been obtained
with the original cDNA sequence, the cDNA sequence was
repaired.
In the case of the chicken cDNA sequence, we used the genomic
sequence to make two small edits to the GenBank gene model
sequence, just after amino acids 1968 and 2327. In the case of
the zebraﬁsh cDNA sequence, we found that the amino terminus
up to aa 327 (of the ﬁnal complete sequence) was missing from
GenBank entry BAD91491.1, the cDNA sequence appeared quite
anomalous over a nine-amino-acid segment with respect to the
other vertebrate sequences (aa 659–668 of the ﬁnal complete
sequence), and there were a number of additional ambiguity codes
in the sequence. To obtain the missing amino end sequence, we
used tBLASTn and splice-junction prediction on the Danio rerio
build 7 genome sequence to create a gene model from the start
codon into the ninth coding exon, PCR ampliﬁed it from cDNA
prepared from one individual zebraﬁsh (kindly provided by Laure
Bernard), and sequenced it. We corrected the anomaly from 659–
668 by reference to theDanio rerio genome sequence and corrected
the remaining ambiguities by reference to the ENSEMBLE Danio
rerio ATM gene model ENSDARP00000080608.
The sequences were then realigned, resulting in the alignment
used for the analyses of missense substitutions described below.
We counted substitutions per position in the alignment by using
the Protpars routine in PHYLIP v 3.68 with the known underlying
phylogeny, and we also used SIFT to conﬁrm that the alignment
met that program’s ‘‘median sequence conservation’’ criterion
for conﬁdent prediction of substitutions that should ‘‘affect
protein function’’30,33. Table 1 gives an idea of how much repair
by gene prediction and repair by cDNA sequencing were applied
to the sequences in the alignment. The complete alignment is
available online as File S1, and the alignment (or updated versions
thereof) is available for online use at the Align-GranthamThe AmerVariation Grantham Deviation (Align-GVGD) web site (see Web
Resources).
ATMmissense substitutions reported in this studywere scored by
the use of this alignment with the missense analysis programs
Align-GVGD and SIFT.17,30 With the use of Align-GVGD, the
relevant output is the ‘‘C-score,’’ which provides seven discrete
grades running from C0 (most likely neutral) to C65 (most likely
deleterious). SIFT scores run from 1.00 (most likely neutral) to
0.00 (most likely deleterious) in steps of 0.01. Two speciﬁc variants
required amore detailed treatment. For the di-amino acid substitu-
tion p.SV2855_2856RI, we scored both component substitutions
(p.S2855R and p.V2856I). p.S2855R received the most severe
possible scores, C65 and 0.00, respectively, from the two programs.
Accordingly, we scored p.SV2855_2856RI as C65 and 0.00. The
three-amino-acid in-framedeletionp.SRI2546_2548del3 (hereafter
referred to asDSRI) wasmore difﬁcult to score. The variant encodes
a stable, essentially full-length protein;34 this makes it biologically
more like a missense substitution than a protein-truncating
variant, so we therefore gave it a score that would allow it to be
included in the logistic regressionswith themissense substitutions.
To do so, we examined the scores of all possible missense substitu-
tions to codons S2546, R2547, and I2548, as well as the degree of
conservation of the surrounding sequences. We noted the
following three points. (1) With SIFT, some individual missense
substitutions at R2547 received a score of 0.00. (2) With Align-
GVGD, themost severe possible substitutions at the three positions
scored C0, C35, and C15, respectively. In the logistic regression
trend tests, the x axis positions for C0, C35, and C15 were 1, 4,
and 2, respectively. The sum of these x axis positions, 7, was the x
axis position of C65. (3) This in-frame deletion is closely ﬂanked
by invariant residues, the spacing between which is also invariant
in our alignment. Combining across these considerations, we
chose to score DSRI as C65 and 0.00.ican Journal of Human Genetics 85, 427–446, October 9, 2009 429
Selection of Cases and Controls for Additional
Mutation Screening
Study 8
Breast cancer case individuals mutation screened at Regensburg
were Australian women selected from the Kathleen Cuningham
Foundation Consortium for Research into Familial Aspects of
Breast Cancer (kConFab) pedigrees35 with the use of these criteria:
no known pathogenic mutation in BRCA1, BRCA2, PTEN (MIM
601728), or TP53 (MIM 191170) (more than 95% of the cases
have been screened for mutations in BRCA1 and BRCA2); ‘Man-
chester score’ for BRCA2 of > 5;36 and at least two blood samples
available from female family members affected with breast cancer
(to allow for future family genotyping and segregation analysis).
The female who was affected with breast cancer at the youngest
age and had available DNA was then selected for ATM screening.
Female Australian control samples sequenced at Regensburg were
recruited as controls for the Australian Cancer Study (ACS).37
None had a personal history of breast cancer at the time of recruit-
ment. These cases and controls were recruited from all Australian
states and territories during the last ten years. The self-reported
ethnicity of the kConFab cases comprised 97% white, 1% other,
and 2% unknown or not reported. The self-reported race and/or
ethnicity of the ACS controls comprised 95% white, 2% Asian,
and 3% other (including unknown and Torres Strait islander).
This study had approval from theQueensland Institute forMedical
Research (QIMR), the Regensburg University institutional review
board (IRB), and all other participating centers’ IRBs. The kConFab
and ACS data are referred to as study 8.
Study 9
The case-control-series mutation screened at the International
Agency for Research on Cancer (IARC) consisted of subjects subse-
lected from ﬁve sources: kConFab35 (13 of these cases were also
screened at Regensburg, thereby providing quality control data),
the three population-based centers of the Breast Cancer Family
Registries (BCFR) (Cancer Care Ontario, the Northern California
Cancer Center, and the University of Melbourne),38 and the
National Cancer Institute of Thailand.39 Subjects were recruited
between 1995 and 2005, and the genetics studies included in
this project had approval from the IARC IRB and the local IRBs
of every center from which we received samples.
Selection of Cases
Selection criteria for cases were a combination of age at diagnosis,
family history of breast cancer, and race and/or ethnicity, as
follows:
Age at Diagnosis. Noting that in the US, Canada, and Australia,
the 20th percentile age of diagnosis for breast cancer is approxi-
mately 51 (Age20) and the ﬁrst percentile age at diagnosis is
approximately 33 (Age1), we applied the following equation:
(Age20  Dx) 3 (20 / [Age20  Age1]) points (scores can be
negative).
This resulted in cases diagnosed at age1 receiving 20 age points,
cases diagnosed at age20 receiving 0 age points, and older cases
receiving negative age points.
Family History. The family history component of the score
depended on whether or not the index case had bilateral breast
cancer, the number of ﬁrst-degree relatives with breast cancer,
the number of second-degree relatives with breast cancer, and
the number of third-degree relatives with breast cancer. The score
was calculated as: index case with bilateral breast cancer: 9 points;
each ﬁrst-degree relative with breast cancer: 6 points; each second-
degree relative with breast cancer: 3 points; and each third-degree
relative with breast cancer: 1 point.430 The American Journal of Human Genetics 85, 427–446, OctobeThe total score was the sum of the age at diagnosis and family
history components. For kConFab and the three Breast CFR
centers, our minimum criterion was a score of 15 points. For the
Thai samples, our minimum criterion was a score of 10 points.
Thus, kConFab and CFR cases diagnosed at less than age 37 years
(less than age 43 years for the Thai cases) qualiﬁed even if they had
no family history. Progressively older cases required progressively
stronger family histories in order to qualify. Finally, we also
applied an absolute age at diagnosis cutoff at diagnosis of age
50 years.
Race and/or Ethnicity. Using the self-reported race and/or
ethnicity and grandparent country-of-origin information avail-
able in the kConFab and BCFR databases, we selected cases of
European or East Asian ancestry from the Cancer Care Ontario
and University of Melbourne BCFR centers; we selected cases of
East Asian ancestry from the Northern California BCFR center;
and we limited our selection of kConFab cases to individuals of
European ancestry. We assumed that cases from the National
Cancer Institute of Thailand are of East Asian ancestry. Finally,
our kConFab cases were selected very early in the project and
were selected under the additional constraints of only one subject
per pedigree and availability of a lymphoblastoid cell line (LCL) for
that subject. These LCLs were used extensively for process devel-
opment. The racial and/or ethnic composition of the resulting
case series was 62.9% European and 37.1% East Asian.
Selection of Controls
Controls were obtained from the three population-based BCFR
centers and the National Cancer Institute of Thailand. The selec-
tion criteria applied were that they were from the same racial
and/or ethnic group as the cases selected from that center and
that their age at ascertainment was not more than three years
beyond the age range of the cases from the same center. The racial
and/or ethnic composition of the resulting control series was
62.7% European and 37.3% East Asian.
The number and age distribution of the cases and controls
screened in studies 8 and 9 is given in Table 2.
Mutation Screening
Mutation screening of the ATM gene at Regensburg from 377
familial breast cancer cases and 362 controls (study 8) was per-
formed by PCR from genomic DNA followed by dye-terminator
sequencing. All 65 ATM exons including the promoter region
were PCR ampliﬁed and bidirectionally sequenced with the use
of 64 primer pairs. Sixty-two primer pairs were tailed with the
M13 sequences 50-TGTAAAACGACGGCCAGT-30 and 50-CAGGA
AACAGCTATGACC-30, which served as universal forward and
reverse sequencing primers, respectively. Two fragments were
ampliﬁed and sequenced with the use of primers without the
M13 tails.
We set up 15 mL PCR reactions in 384-well plates, using the
Liquidator96 multi-channel pipettor (Steinbrenner Laborsysteme
GmbH). Each reaction contained 30 ng of DNA, 1 U AmpliTaq
Gold (Applied Biosystems, Foster City, CA, USA), 8% glycerol,
10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM MgCl2, and
2.4 pmol of each primer. The cycling conditions were as follows:
94C for 5 min, 40 cycles of 94C for 30 s, 60C for 45 s, 72C
for 45 s, ﬁnal extension at 72C for 10 s. We puriﬁed 10 mL of
the ampliﬁcation product with the AmpureKit (Agencourt
Bioscience), using a 96-channel pipetting robot (BiomekNX, Beck-
man Coulter). We performed the puriﬁcation in accordance with
the manufacturer’s protocol. The PCR products were eluted from
themagnetic beads and diluted 4- to 6-fold with 40 ml LC-MSwaterr 9, 2009
Table 2. Distribution of Subjects from Studies 8 and 9 by Center and Age
Study Designation (Subject Source) Mutation-Screening Site Cases Average (Range) Controls Average (Range)
8 (kConFab) Regensburg 364 44.3 (21–71) –
8 (ACS) Regensburg – 362 58.0 (19–80)
9a (kConFab)a IARC 21 40.0 (28–48) –
9a (Melbourne CFR)a,b IARC 260 34.7 (23–49) 262 36.9 (22–45)
9a (Ontario CFR)a IARC 112 37.4 (25–48) 153 40.0 (25–50)
9b (No. Cal CFR)c IARC 90 35.6 (23–49) 42 43.9 (31–52)
9b (Thai NCI)c IARC 140 35.3 (17–47) 202 35.0 (18–46)
a Except for three subjects noted immediately below (footnote b), all of the subjects in these studies were of recent European ancestry.
b The Melbourne CFR sample series included one case and two controls of recent East Asian ancestry. In logistic regressions of the bona fide case-control studies,
these were considered as part of study 9b.
c All of the subjects in these studies were of recent East Asian ancestry.(Merck), depending on the amount of amplicon determined in
agarose gels by ethidium bromide staining.
Cycle sequencing was performed in a ﬁnal reaction volume of
10 ml that contained 0.25 ml BigDye Terminator v.3.1 (Applied
Biosystems), 3.2 pmol primer, 13 reaction buffer, 5 ml HPLC water,
and 2 ml of the diluted puriﬁed PCR product. Cycle sequencing
conditions were as follows: 96C for 1 min, 25 cycles of 96C for
10 s, 50C for 5 s, 60C for 90 s. The sequencing products were
puriﬁed with the CleanSeq Kit (Agencourt), in accordance with
the manufacturer’s protocol, with the use of a 96-channel pipet-
ting robot (Biomek NX). The products were eluted from the
magnetic beads with 20 ml 75% HiDi-Formamide (Applied
Biosystems). We transferred 17 mL to the ﬁnal plate and analyzed
the DNA fragments with an AB-3730 48-Capillary Sequencer.
Sequence traces were aligned and analyzed with SeqScape v.2.5
(Applied Biosystems). Sequences of the mutation-screening
primers used are available from P.O.
Mutation screening of the ATM gene at IARC (study 9) was per-
formed fromwhole-genome ampliﬁed (WGA) DNAwith the use of
a nested PCR strategy, followed by high-resolution melting curve
analysis (HRM analysis),40,41 and then dye-terminator resequenc-
ing of samples that contained a melt curve aberration indicative
of the presence of a sequence variant.
For ATM amplicons harboring SNPs with frequencyR 1% in the
population, we applied a simultaneous mutation scanning and
genotyping approach by using HRM analysis to improve the sensi-
tivity and the efﬁciency of the mutation screening.42 This method
combines both ﬂuorescent LCGreen Plus dye and unlabeled oligo-
nucleotide probes that target the common SNP in an asymmetric
PCR, leading to simultaneous production of probe-target and
whole-amplicon double-stranded DNA duplexes that can be
analyzed from the same HRM run. It thereby allows stratiﬁcation
of the samples according to their probe-target melting, i.e to their
genotype for the common SNP. Hence, the data analysis compo-
nent of mutation scanning is performed separately on heterozy-
gous and homozygous sample subsets.
Whole-genome ampliﬁcations were performed on genomic
DNAs with the use of the GenomiPhi DNA Ampliﬁcation Kit
(GE Healthcare). Fifty nanograms of genomic DNA and 9 ml of
a sample buffer containing random hexamer primers were heat
denatured and cooled, allowing random priming of the hexamers,
then 9 ml of reaction buffer and 1 ml of Phi29 DNA polymerase were
added and incubated overnight at 30C for linear DNA synthesis.The AmerConcentrations of WGA DNAs were measured by standard
picogreen titration. WGA DNAs were normalized at 6 ng/mL, and
30 ng of WGA DNAs were plated and dried into 384-well plates
before being stored at 4C for further use.
Primary PCR (PCR1), usually set up as a three amplicon triplex,
was performed in an 8 ml reaction volume containing 30 ng of
template DNA that had been prealiquoted and dried into the
sample well, 10% sucrose, 20 mM Tris base, 3.2 mM acetic acid,
10 mM Na citrate, 16 mM MgSO4, 0.01% Triton X-100, 200 nM
dNTP, 200 nM forward and reverse primers for each amplicon,
and 0.04 U/mL of Platinum Taq Polymerase (Invitrogen). The
PCR consisted of 25 cycles of ampliﬁcation with priming temper-
ature and elongation time optimized for each ampliconmultiplex.
For standard HRMmutation scanning, simplex secondary PCRs
(PCR2) were then performed in 6 ml reaction volume containing
1.5 ml of 1:100 diluted PCR1 product, 1X Invitrogen PCR buffer
(20 mM Tris-HCl pH 8.4, 50 mM KCl), 1.5 mM MgCl2, 500 nM
dNTP, 400 nM forward and reverse primers, 0.5X LCGreen Plus
(Idaho Technology), and 0.04 U/mL of Platinum Taq Polymerase.
For the simultaneous mutation scanning and genotyping proce-
dure, the same conditions were used, except that (1) a primer
asymmetry ratio of 1:5 (100 nM limiting primer, 500 nM excess
primer) was used to favor the production of the DNA strand
targeted by the probe, and (2) the unlabelled 30 end-capped probe
was included at 500 nM. For an optimal efﬁciency of HRM, PCR2
amplicons were no longer than 350 bp and ampliﬁed with 40
cycles for standard mutation scanning and 55 cycles for simulta-
neous mutation scanning and genotyping.
Prior to HRM analysis, PCR2 products were heated to 94C, then
slowly cooled to 20C to promote heteroduplex formation and
detection. Melting was monitored from 65C to 95C for standard
mutation scanning and 35C to 95C for simultaneous mutation
scanning and genotyping on a LightScanner instrument (Idaho
Technology). HRM analyses were carried out with the LightScan-
ner software (Idaho Technology) with the ‘‘Scanning’’ mode used
for standard mutation scanning and, in the case of common
SNPs, the ‘‘Genotyping’’ mode used for the region of the probe
melting followed by an analysis with the ‘‘Scanning’’ mode for
the region of DNA melting.
PCR2 products with melting curves that differed from the refer-
ence group were rearrayed onto new 96-well plates and treated
with exonuclease I and shrimp alkaline phosphatase for the
removal of excess primers and nucleotide triphosphates (exo-SAPican Journal of Human Genetics 85, 427–446, October 9, 2009 431
treatment). Dye-terminator sequencing reactions (BigDye Termi-
nator, version1.1, Applied Biosystems) were inoculated with the
exo-SAP-treated PCR products, thermocycled, then puriﬁed with
Montage SEQ96 sequencing reaction cleanup kits (Millipore).
Sequencing reactionproductswere then runon a96-capillary Spec-
trumedix Sequencer (Transgenomics) in accordance with the
manufacturer’s recommendations.
The resulting chromatograms were analyzed with the program
Java SnpScreen. Very similar to the software used for research
resequencing and BRACAnalysis at Myriad Genetics,43,44 the
program starts with the canonical text sequence of each amplicon,
aligns all of the forward chromatograms to the canonical sequence,
reverse complements the reverse chromatograms and then
aligns them to the canonical sequence, normalizes the signal
strength from all of the chromatograms, then displays them as
aligned forward-reverse chromatogram pairs. The software
contains algorithms that spot potentially heterozygous positions
on the basis of the joint data from the target sequence and each
forward and reverse chromatogram pair. Alternatively, the user
can scan the superimposed chromatogram sets visually. After the
screening has been completed, the program creates an output
report that contains anamplicon-speciﬁc genotype for each sample
screened.
All samples found to carry a rare sequence variant were reampli-
ﬁed from genomic DNA for conﬁrmation of the presence of the
variant.
Every step of our automated laboratory process was tracked by
a Laboratory Information Management System (LIMS) that had
been internally developed.45 Sequences of the mutation-screening
primers used are available from S.V.T., and the code for Java
SnpScreen is available from A.T.
DNAs from 13 kConFab breast cancer cases were mutation
screened at both Regensburg and IARC, as were those of 30 other
individuals that are part of another study being conducted by
these centers. The independently determined genotypes were
identical for all 43 individuals. Results from the kConFab samples
that were analyzed twice are included in the study 9 results.
Statistical Methods
To assess evidence of risk from the case-control frequency distribu-
tion of protein-truncating variants (T), known or very likely spli-
ceogenic splice-junction variants (SJ), and rare missense substitu-
tions (rMSs), we constructed a single table with one entry per
subject, zero or one rare sequence variant per subject, and annota-
tions for study, case-control status, probability of being of recent
African ancestry, and the estimated efﬁciency of mutation-
screening method used.
For mutation-screening data extracted from the seven published
case-control studies and 17 published case-only or control-only
studies, our assumption of no more than one rare variant per
subject was necessary because the studies pooled did not systemat-
ically report co-occurrence between rare variants. Because the
summed allele frequencies of the rare variants in these studies
(excluding the four that used the protein-truncation test [PTT)
only) was about 4.2%, we would expect that by chance, about
0.18% (~six subjects in the entire pooled data set) might have
been compound heterozygotes; unless the compound heterozy-
gotes were spread very unevenly among the various grades of
sequence variants, the slight implied counting error should have
had minimal effect on our overall results. For subjects in our
own mutation screening study who carried more than one rare
variant, only the variant belonging to the most likely pathogenic432 The American Journal of Human Genetics 85, 427–446, Octobegrade was considered. We did not observe co-occurrence between
any two rare variants of grade C35 or higher.
Because of variation in study parameters between study sites,
including case and/or control selection criteria, ethnic groups
sampled, and mutation-screening methodology, multivariable
unconditional logistic regression analyses were performed. Anal-
yses of the bona ﬁde case-control studies were adjusted for study
site. The European and East Asian components of study 9 were
treated as two separate studies, 9a and 9b, for this purpose.
However, adjustment for study site was not possible for expanded
analyses that included the case-only and control-only studies. For
these subsidiary expanded analyses, we adjusted for ethnicity and
mutation-screening methodology as described below.
The frequency of rare variants in individuals of recent African
ancestry is approximately twice as high as it is in individuals of
European, Asian, or Latino/Hispanic ancestry.46 Accordingly,
ethnicity was treated as a continuous variable reﬂecting the prob-
ability of a subject to be of recent African ancestry and was esti-
mated from the case and control selection criteria described in
each study.
Mutation detection is rarely 100% sensitive, and there are
notable sensitivity differences between methods. Therefore, we
treated mutation-screening-method sensitivity as a continuous
variable equal to 1/s, with s corresponding to the sensitivity of
the method. The values were based on a recent review of muta-
tion-screening methods47 and were deﬁned as follows: 0.95 for
HRM, denaturing high-performance liquid chromatography
(DHPLC) and sequencing, 0.90 for denaturing gradient gel electro-
phoresis (DGGE), 0.75 for single-strand conformation polymor-
phism (SSCP), 0.70 for ﬂuorescent chemical cleavage of mismatch
(FCCM), and conformation-sensitive gel electrophoresis (CSGE).
We considered that the PTT had a sensitivity of 0.95 for detection
of protein-truncating variants, and we considered that the mixed
application of DHPLC and restriction endonuclease ﬁnger-
printing analysis had a sensitivity of 0.60 for detection of missense
substitutions. Finally, we estimated that the nonisotopic RNase
cleavage-based assay (NIRCA) had a sensitivity of 0.50.
Logistic regression trend tests were formatted such that subjects
who did not carry any rare variant and carriers of the seven grades
of rMSs (C0, C15, C25, C35, C45, C55, and C65) deﬁned by Align-
GVGD17 were assigned the default row labels 0,1,2,3,4,5,6, and 7,
respectively. These row labels were then used as a continuous vari-
able in the logistic regressions. Regression coefﬁcients and trend
test p values (‘‘Ptrend’’) were estimated from the resulting ln(OR)s
with the logit function of STATA. We used the Fisher’s exact test
(FET) to obtain the lower bound of the 95% conﬁdence interval
for single-category tests that had one or more cases but zero
controls.
The reference noncarrier group (assigned logistic regression row
label 0) comprised the subjects who were not reported to carry
a rMS, an in-frame deletion, or a TþSJ variant anywhere in the
gene. Thus, the same reference group of noncarriers was used for
whole-gene analyses and domain-speciﬁc subanalyses.
Post hoc power calculations were performed by specifying
a hypothetical OR and population prevalence for each class of
variant, together with the total probability of breast cancer prior
to age 70. The ORs that we speciﬁed for the individual grades of
sequence variants, relative to C0 and the noncarriers, were as
calculated from the whole-gene analysis for the grades for which
there were reasonable numbers of observations: 1.13, 1.23, 1.20,
4.82, and 2.33 for C15, C25, C55, C65, and TþSJ, respectively.
Because of the very low numbers of observations in C35 andr 9, 2009
C45, those ORs were set equal to C55 at 1.20. From these, we calcu-
lated expected values and variances of the test statistics for the
types of test considered: Pearson’s chi-square for the two-category
tests, and the Wald statistic from a logistic regression for the trend
test. We then calculated the probability of these statistics
exceeding the thresholds corresponding to p < 0.05 in each
case, using a normal approximation.
Results
Published Data Available for Meta-Analysis
Review of the literature revealed seven studies reporting
nonredundant primary data from the mutation screening
of ATM in breast cancer cases and controls,6,10,12,14,48–50
as well as 17 additional studies that reported case-only or
control-only mutation screening with ascertainment
criteria that met our inclusion requirements.5,7–9,11,13,51–61
These studies provided bona ﬁde case-control data from
a total of 1544 cases and 1224 controls plus case-only
and control-only data from an additional 1581 cases and
154 controls (Table 3 and Table S1, available online). The
set of sequence variants reported from these 4503 subjects
included seven common missense substitutions (carrier
frequency R 1%), 121 rare missense substitutions
(frequency < 1%; rMSs), 20 protein-truncating variants
(T), and 10 variants thought or expected to cause severe
splice-junction defects (SJ) (Table S2). We considered anal-
ysis of the seven common ATM missense substitutions
to be outside of the scope of this work. Thus all results
from this point on are based on analyses of rMS, T, and
SJ variants.
Additional Mutation Screening
To increase the power of our analyses, we mutation
screened the coding exons and adjacent proximal introns
of ATM in 987 cases and 1021 controls: 364 cases and
362 controls were screened by direct sequencing (study
8), and 623 cases and 659 controls were screened by
HRM, followed by sequencing of the individual samples
that yielded an HRM aberration (study 9). The mutation
screening revealed 76 rMSs, one in-frame deletion of three
amino acids (DSRI) that we treated as a missense substitu-
tion, 12 protein-truncating variants, and one variant
expected to destroy a splice acceptor. Only 28 of the
77 rMSs and two of the 13 TþSJ variants were present in
the published mutation-screening data (Table S2).
Analysis of Truncating and Splice-Junction Variants
In analyses of known or candidate susceptibility genes in
which simple loss of function is expected to be pathogenic,
it is now becoming customary to pool data from rare trun-
cating variants with data from rare splice-junction variants
that are known to (or thought highly likely to) destroy
a splice junction with the ultimate result of nonsense-
mediated decay and a protein truncation because their
effects on disease risk are often similar.14,62–65 Before we
pooled the ATM TþSJ data, we reviewed the sequenceThe Amercontext of all of the SJ variants that had been treated as
likely pathogenic in previous studies. We found ten that
appear to be correctly classiﬁed, but we also found two,
c.1066-6T>G and c.3993þ5G>T, that ought not be
included in the TþSJ pool in the absence of further func-
tional assay results. The variant c.1066-6T>G is no longer
thought to be pathogenic for A-T because the homozygous
A-T patient previously described7 has recently been found
Table 3. Number of Cases and/or Controls by Study
Study
Designation Study Cases Controls Total
1 Fitzgerald et al. 199748 401 202 603
2 Teraoka et al. 20016 142 81 223
3 Sommer et al. 200310 90 90 180
4 Thorstenson et al. 200312 a 270 52 322
5 Renwick et al. 200614 a 443 521 964
6 Hirsch et al. 200849 a 37 95 132
7 Soukupova et al. 200850 a 161 183 344
8 This study, kConFab/
Regensburga
364 362 726
9a This study, IARC- European 392 414 806
9b This study, IARC- East Asian 231 245 476
Bona Fide Case-Control Subtotal 2531 2245 4776
10 Vorechovsky et al. 199651 38 0 38
11 Chen et al. 199852 a 100 0 100
12 Bebb et al. 199953 47 0 47
13 Izatt et al. 19995 a 100 0 100
14 Do¨rk et al. 20017 192 0 192
15 Drumea et al. 200054 37 0 37
16 Atencio et al. 20018 52 0 52
17 Maillet et al. 20029 94 0 94
18 Angele et al. 200311 51 0 51
19 Buchholz et al. 200413 91 0 91
20 Ho et al. 200757 131 0 131
21 Broeks et al. 200858 437 0 437
22 Brunet et al. 200859 43 0 43
23 Tapia et al. 200860 a 42 0 42
24 Gonzalez-Hormazabal
et al. 200861 a
126 0 126
25 Thorstenson et al. 200155 b 0 64 64
26 NIEHS56 0 90 90
All Studies Total 4112 2399 6511
a Studies in which more than 50% of the cases had a family history of breast
cancer.
b We have used only 64 of the 93 controls described in Thorstenson et al
(2001).55 The remaining 29 controls were of Middle Eastern, South Asian, or
Oceanian descent, and there were essentially no breast cancer cases from these
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to harbor second-site mutations that are sufﬁcient to
explain the A-T phenotype on their own (Richard Gatti,
personal communication). In addition, in silico analyses
of the variant with splice site prediction by neural network
(NNsplice) and maximum entropy modeling of short
sequence motifs (MaxEntScan)66,67 are not indicative of
a severe effect on the ﬁtness of the intron 10 splice
acceptor; both programs give scores for this sequence
variant that are above the mean for the pool of all wild-
type splice acceptors in ATMþBRCA1þBRCA2. Similarly,
despite the argument that Do¨rk et al. made in favor of
the idea that c.3993þ5G>T should interfere with splicing,7
both NNsplice and MaxEntScan score this variant above
the mean for the pool of all wild-type splice donors in
ATMþBRCA1þBRCA2.
Table 4. Analysis of Truncating and Spliceogenic Splice-Junction
Variants
Cases Controls
Crude OR
[95% CI]
Adjusted OR
[95% CI]a
Bona Fide Case-Control Studiesb
Noncarrier 2505 2235 ref ref
TþSJ 26 10 2.33 [1.12–4.84] 2.32 [1.12–4.83]
All Studies
Noncarrier 4076 2389 ref ref
TþSJ 36 10 2.10 [1.04–4.24] 2.08 [1.03–4.21]
Abbreviations are as follows: OR, odds ratio; CI, confidence interval;ref, refer-
ence category (OR ¼ 1.0).
a The OR from the analysis of the bona fide case-control studies was adjusted
for study. The OR from the analysis of all studies was adjusted for ethnicity and
sensitivity of the mutation-screening method employed.
b The bona fide case-control studies included both mutation-screened cases
and mutation-screened controls that met our ascertainment criteria.434 The American Journal of Human Genetics 85, 427–446, OctobeExcluding these two sequence variants, a total of 41
distinct TþSJ variants were present in the combination
of the published ATM breast cancer case and control
mutation-screening literature plus our own mutation-
screening data. One, c.3802delG, has been reported four
times, two have been reported twice each, and the remain-
ing 38 were reported once each (Table S2). With a focus
on the bona ﬁde case control studies, there were a total
of 26 TþSJ variants observed among 2531 cases and ten
among 2245 controls (OR ¼ 2.32, p ¼ 0.024) (Table 4).
Expansion for inclusion of the 15 case-only and two
control-only data sets had little effect on these results
(OR ¼ 2.08, p ¼ 0.042).
Analysis of Rare Missense Substitutions
There is as yet no community consensus on how to handle
rMSs. With 170 distinct rMSs in the present ATM data set,
117 of which were observed only once, it is clear that any
analysis of individual rMSs will be overwhelmed by either
the number of degrees of freedom inherent in the analysis
or the adjustment of signiﬁcance thresholds required to
take account of multiple testing, depending on the format
of the test. However, when all of the rMSs reported in the
bona ﬁde case-control studies were pooled, there was no
notable difference in their pooled frequency in cases versus
controls (OR ¼ 1.14, p ¼ 0.29) (Table 5). Recently, Li and
Leal suggested using frequency to collapse rare variants
into a limited set of n pools, followed by an n-1 degree of
freedom test for heterogeneity over the pools.68 When
we collapsed the rMS case-control distribution into a series
of four pools based on apparent frequency, we again
found no obvious difference between cases and controls
(p ¼ 0.39) (Table 5).Table 5. Whole-Gene Analysis of Rare Missense Substitutions, Unstratified or Stratified by Frequency
Bona Fide Case-Control Studies All Studies
Test of Significance: OR [95% CI],
p Value, or Regression Coefficient
[95% CI]
Test of Significance: OR [95% CI],
p Value, or regression coefficient
[95% CI]
Cases Controls Crude Adjusteda Cases Controls Crude Adjustedb
Noncarrierc 1788 1717 ref ref 3125 1850 ref ref
Any rMSd 160 135 1.14 [0.90–1.44] 1.14 [0.90–1.44] 248 156 0.94 [0.76–1.16] 1.06 [0.86–1.31]
Stratiﬁcation by Frequency
rMSs observed 13–33 69 63 1.05 [0.74–1.49] 1.05 [0.74–1.49] 113 79 0.86 [0.64–1.15] 0.89 [0.66–1.20]
rMSs observed 43–103 55 43 1.23 [0.82–1.84] 1.23 [0.82–1.84] 74 46 0.95 [0.66–1.38] 1.01 [0.69–1.47]
rMSs observed 113–303 20 21 0.91 [0.49–1.69] 0.91 [0.49–1.69] 37 23 0.95 [0.56–1.61] 0.96 [0.57–1.62]
rMSs observed > 303 23 12 1.84 [0.91–3.71] 1.84 [0.91–3.71] 33 12 1.63 [0.84–3.16] 1.59 [0.82–3.10]
Test of heterogeneity p ¼ 0.39 p ¼ 0.39 p ¼ 0.49 p ¼ 0.62
Abbreviations are as follows: OR, odds ratio; CI, confidence interval; ref, reference category (OR ¼ 1.0).
a Use of unconditional logistic regression with an adjustment for study.
b Use of unconditional logistic regression with adjustments for ethnicity and sensitivity of mutation-screening method employed.
c Carriers of TþSJ variants are excluded.
d Individuals in studies 8 or 9 who carried two (10) or three (1) rare variants are coded according to the highest grade of rare variant that they carried. The
co-occurrences are detailed in the footnotes to Table S2.r 9, 2009
Previously, we suggested collapsing rMSs into a graded
series of pools ordered by the probability that missense
substitutions in each pool are evolutionarily deleterious
and then conducting a test for trend over the ordered
pools.17 A number of missense-substitution-analysis pro-
grams, including Align-GVGD, MAPP, and SIFT, output
a variable that can be used to order missense substitutions
with respect to the probability that they are evolutionarily
deleterious.69–71 A common thread is that these programs
require a protein multiple sequence alignment of the
gene of interest, and their performance is sensitive to the
quality of the alignment used.72 To enable grading of
ATM rMSs, we constructed and carefully curated a protein
multiple sequence alignment from seven full-length verte-
brate plus two additional deuterostomate ATM ortholog
sequences that were determined in the course of this
project. The alignment is similar in phylogenetic depth
to those that we have found useful for analyzing mis-
sense substitutions in BRCA1, BRCA2, and CHEK2.17,73
A maximum parsimony count revealed that the alignment
contains an average of 3.08 amino acid substitutions per
position, and SIFT reported ‘‘median sequence conserva-
tion’’ of 3.07, meeting that program’s criterion for conﬁ-
dent prediction of which substitutions should ‘‘affect
protein function.’’ Thus, the alignment meets externally
deﬁned criteria of sufﬁcient informativeness to support
grading of missense substitutions.71,74 Sequence accession
numbers and pairwise percentage sequence identities are
reported in Table 1.
The missense substitutions were then assessed in silico
with the use of Align-GVGDwith our sequence alignment,
and the raw scores were converted into an ordered series of
seven grades: C0, C15, C25, C35, C45, C55, and C65.17
These grades provide a ranking of missense substitutions
from evolutionarily most likely to least likely. The pooled
rMS observational data are summarized in Table 6, the
complete set of sequence variants is described in Table
S2, and their distribution and frequency are displayed
graphically in Figure 1. After excluding TþSJ carriers from
the data set, we performed a log-linear trend test across
noncarriers (grade 0) and carriers of the seven grades of
missense substitutions. Applied to the bona ﬁde case-
control studies, the trend test, which is against the null
hypothesis of no change in OR with increasing grade of
missense substitution, yielded a ln(OR) increase of 0.13
per grade (Ptrend ¼ 0.0035). Expansion for inclusion of
the case-only and control-only data sets had little effect
on these results (ln(OR) increase of 0.11 per grade and
Ptrend ¼ 0.0073).
Combining mutation-screening data from a population
sampling with ATM sequence variation between primates,
Oefner and co-workers argued that there is stronger selec-
tion against missense substitutions falling in the car-
boxy-third of ATM than in the rest of the gene.55 Accord-
ingly, we analyzed separately the missense substitutions
located in this region of the protein. Using the relatively
relaxed Prosite deﬁnition of residue Ile1960 as the start ofThe Amerthe FAT domain (Prosite entry PS51189, last updated
February 2009) to provide a domain-based deﬁnition of
the carboxy-third of ATM, we reran the same set of
missense trend tests described above (Table 6). Applied to
the bona ﬁde case-control studies, the rMS trend test over
the carboxy-third of the protein yielded a ln(OR) increase
of 0.31 per grade (Ptrend ¼ 0.00048). In contrast, the trend
test applied to the segment 1-1959 returned a ln(OR)
increase of 0.0095 per grade (Ptrend ¼ 0.87). Expanded to
include all of the studies, the ln(OR) increase for the car-
boxy-third was 0.24 per grade (Ptrend ¼ 0.0016). That the
whole-gene, amino two-thirds, and carboxy-third analyses
produce different ln(OR) coefﬁcients for overlapping sets
of rMSs highlights the point that none of these are perfect
models of reality. No model will ever be exactly correct, so
we preplanned a relatively simple analysis strategy17 that
potentially sacriﬁces OR accuracy to avoid hiddenmultiple
testing that would erode the validity of the p values ob-
tained.
Using the bona-ﬁde case-control data, we performed two
additional analyses of the carboxy-third of the protein.
First, in order to test for a difference between OR trend esti-
mates for the amino two-thirds versus carboxy-third of the
protein, we performed a likelihood-ratio test to compare
two models. In one model, we used an indicator variable
to specify whether the rMSs fall in the carboxy-third of
the protein or not; in the other model, all rMSs were
treated similarly. The result from this likelihood ratio test
was signiﬁcant (p ¼ 0.0021), indicating that risk conferred
by rMSs falling before and after Ile1960 are not equivalent.
Second, we were concerned that the evidence for risk
conferred by rMSs falling in the carboxy-third of the
protein might be entirely due to p.V2424G. This was the
most common of the clearly pathogenic (for A-T) variants
in our data set, observed nine times in the cases and zero
times in the controls. After exclusion of this variant, a trend
test over the carboxy-third of the protein still returned
substantial evidence for risk attributable to rMSs (ln(OR)
increase of 0.25 per grade and Ptrend ¼ 0.0088).
For ATM, the speciﬁc domains in which missense substi-
tutions have been most closely tied to A-T are the FAT,
kinase, and FATC domains.75,76 Therefore, there is also
a rationale for focusing our analysis of missense substitu-
tions very tightly on these three domains. Using the rela-
tively restrictive PFAM FAT (PFAM PF02259, 2096–2489),
PI3_PI4_kinase (PFAM PF00454, 2711–2962), and FATC
(PFAM PF02260, 3024–3056) domain deﬁnitions, we reit-
erated our set of rMS trend tests. In this iteration, Align-
GVGD produced an essentially binary classiﬁcation; the
missense substitutions were either C0 (21 distinct substitu-
tions in all studies) or C55–C65 (13 distinct substitutions
in all studies) (Table 6 and Table S2). When the missense-
substitution trend test was applied to the FATþkinaseþ
FATC rMSs observed in the bona ﬁde case-control
series, we found a ln(OR) increase of 0.41/grade (Ptrend ¼
0.0022). Expanded to include all of the studies, the
ln(OR) increase was 0.40/grade (Ptrend ¼ 0.0030).ican Journal of Human Genetics 85, 427–446, October 9, 2009 435
Table 6. Analyses of Rare Missense Substitutions, Stratified by Align-GVGD Grade
Bona Fide Case-Control Studies All Studies
Test of Significance: ln(OR) [95%CI]
or Regression Coefficient [95%CI]
Test of Significance: ln(OR) [95%CI]
or Regression Coefficient [95%CI]
Cases Controls Crude Adjusteda Cases Controls Crude Adjustedb
Whole-Gene Analysis; Stratiﬁcation by Align-GVGD Grade
Noncarrierc 1788 1717 ref ref 3125 1850 ref ref
C0d 86 89 0.07 [0.38–0.23] 0.08 [0.38–0.23] 140 107 0.26 [0.51–0.00] 0.09 [0.36–0.18]
C15d 34 29 0.12 [0.38–0.62] 0.12 [0.38–0.62] 46 30 0.10 [0.56–0.37] 0.07 [0.54–0.39]
C25d 9 7 0.21 [0.78–1.20] 0.21 [0.78–1.20] 14 8 0.04 [0.84–0.91] 0.011 [0.76–0.98]
C35 0 1 - - 0 1 - -
C45 1 0 - - 1 0 - -
C55 5 4 0.18 [1.13–1.50] 0.18 [-1.13–1.50] 10 5 0.17 [0.91–1.24] 0.19 [0.89–1.27]
C65 25 5 1.57 [0.61–2.53] 1.57 [0.61–2.53] 37 5 1.48 [0.54–2.41] 1.51 [0.58–2.45]
ln(OR) regression
coefﬁcients [95% CI]e
0.13 [0.044–0.22] 0.13 [0.044–0.22] 0.085 [0.0077–0.16] 0.11 [0.026–0.18]
Analysis from Position Ile1960 to the End of the Protein; Stratiﬁcation by Align-GVGD Grade
Noncarrierc 1788 1717 ref ref 3125 1850 ref ref
C0 22 21 0.01 [0.60–0.61] 0.01 [0.59–0.61] 35 25 0.19 [0.70–0.33] 0.08 [0.60–0.44]
C15 3 1 1.06 [1.21–3.32] 1.06 [1.21–3.32] 4 1 0.86 [1.33–3.05] 0.91 [1.28–3.10]
C25 2 2 0.04 [2.00–1.92] 0.04 [2.00–1.92] 3 2 0.12 [1.91–1.67] 0.07 [1.86–1.72]
C35 0 0 - - 0 0 - -
C45 1 0 - - 1 0 - -
C55 4 1 1.35 [0.85–3.54] 1.34 [0.85–3.54] 7 2 0.73 [0.84–2.30] 0.76 [0.82–2.33]
C65 18 1 2.85 [0.84–4.86] 2.85 [0.83–4.86] 24 1 2.65 [0.65–4.66] 2.65 [0.65–4.65]
ln(OR) regression
coefﬁcients [95% CI]e
0.31 [0.14–0.48] 0.31 [0.14–0.48] 0.23 [0.083–0.37] 0.24 [0.091-0.39]
Analysis Limited to the Restrictively Deﬁned FAT, Kinase, and FATC Domains; Stratiﬁcation by Align-GVGD Grade
Noncarrierc 1788 1717 ref ref 3125 1850 ref ref
C0 11 10 0.05 [0.80–0.91] 0.06 [0.80–0.91] 20 12 0.01 [0.73–0.70] 0.09 [0.64–0.81]
C15 0 0 - - 0 0 - -
C25 0 0 - - 0 0 - -
C35 0 0 - - 0 0 - -
C45 0 0 - - 0 0 - -
C55 3 1 1.06 [1.21–3.32] 1.05 [1.21–3.32] 6 1 1.27 [0.85–3.39] 1.28 [0.84–3.40]
C65 17 0 Inﬁnite [1.45f–N] g 22 0 Inﬁnite [3.39e –N] g
ln(OR) regression
coefﬁcients [95% CI]e
0.41 [0.15–0.68] 0.41 [0.15–0.68] 0.38 [0.13–0.63] 0.40 [0.13–0.64]
Bold font is used to indicate point estimates or trend coefficients with p < 0.05. Abbreviations are as follows: OR, odds ratio; CI, confidence interval; ref, reference
category (OR ¼ 1.0).
a Using unconditional logistic regression with an adjustment for study.
b Using unconditional logistic regression with adjustments for ethnicity and sensitivity of mutation-screening method employed.
c Carriers of TþSJ variants are excluded. Carriers of rMSs that fall outside of the specified region (and no rMS occurring in the region) are excluded.
d Individuals in studies 8 or 9 who carried two (8) or three (1) rare variants are coded according to the highest grade of rare variant that they carried. Categories
that lose a subject(s) are marked ‘‘d.’’ The co-occurrences are detailed in the footnotes to Table S2.
e From a standard logistic regression of form ln(OR) ¼ a þ b(x) in which a ¼ 0, b is the logistic regression OR trend coefficient, and x is, in this case, missense-
substitution grade. Note that the regression coefficient is significant if its 95% CI excludes 0.00.
f Lower boundary of this 95% CI was obtained from Fisher’s exact test.
g Could not be calculated with the use of the adjusted model.436 The American Journal of Human Genetics 85, 427–446, October 9, 2009
Noting the estimated OR for TþSJ variants (2.32, 95%
conﬁdence interval [CI] 1.12–4.83) and the OR predicted
at C65 from the ﬁtted trend of the FATþkinaseþFATC anal-
ysis (18.0, 95% CI 2.82–117) (Table 4 and calculation from
Table 6), we asked whether the risk conferred by inheri-
tance of FATþkinaseþFATC C65 missense substitutions is
higher than that for TþSJ variants. A Fisher’s exact test
revealed that the proportion of cases among FATþkinaseþ
FATC C65 missense-substitution carriers (17/17 when
conﬁned to case-control studies, 22/22 for all studies)
was different from the proportion of cases among TþSJ
carriers (26/36 when conﬁned to case-control studies, 36/
46 for all studies) (PFET ¼ 0.021 and 0.024 for the two
comparisons, respectively). When we excluded from the
FATþkinaseþFATC rMS versus TþSJ comparison the four
studies (1, 7, 11, and 12) that used only the protein-
truncation test for their mutation screen, the differences
remained signiﬁcant (PFET ¼ 0.019 for case-control only
and PFET ¼ 0.022 for all studies). Thus, results from the
two-sided Fisher’s exact tests support the interpretation,
derived from the logistic regression OR point estimates,
that FATþkinaseþFATC C65 rMSs confer on average
greater risk than do TþSJ variants.
Comparison between Align-GVGD and SIFT
The ability to detect statistical evidence of risk attributable
to rMSs in ATM was not unique to Align-GVGD. For
example, we used SIFT to set up a binary comparison
between noncarriers and carriers of rMSs with SIFT score%
0.05, which is the standard binary classiﬁcation cutoff
with this algorithm. In the whole-gene missense analysis
of the bona ﬁde case-control data, the SIFT analysis
returned OR ¼ 1.58 (p ¼ 0.014), a result that would clearly
contribute toward evidence that ATM is a breast cancer
susceptibility gene (data not shown). Conﬁned to rMSs
in the carboxy-third of the protein, this SIFT analysis
returned OR ¼ 3.60 (p ¼ 0.0014), reiterating the strength
of this subset analysis. Finally, for the restrictive FATþ
kinaseþFATC analysis, we obtained OR ¼ 5.27 (p ¼
0.0023). However, analysis with SIFT did not provide any
evidence that a subset of rMSs might confer greater risk
than do TþSJ variants. For example, a Fisher’s exact test
did not indicate any difference in the proportion of cases
among FATþkinaseþFATC SIFT% 0.05 missense-substitu-
tion carriers (22/26 when conﬁned to case-control studies)
and the proportion of cases among TþSJ carriers (PFET ¼
0.36, or p ¼ 0.34 after exclusion of studies 1 and 7). The
most severe grade of missense substitutions that SIFT can
deﬁne is SIFT score ¼ 0.00. Even upon restriction of the
rMS analysis to the proportion of cases among FATþ
kinaseþFATC SIFT ¼ 0.00 missense-substitution carriers
(19/21 when conﬁned to case-control studies), the differ-
ence with the proportion of cases who carry TþSJ variants
remained null (PFET ¼ 0.18, or p ¼ 0.16 after exclusion of
studies 1 and 7).
We suspected that an analysis using Align-GVGD
detected a difference between the most severe grade ofThe AmerFATþkinaseþFATC missense substitutions versus TþSJ
variants whereas an analysis using SIFT did not because
Align-GVGD C65 provides, on average, a slightly higher
standard for missense-substitution severity than does
SIFT score ¼ 0.00. For example, across the whole gene
and with the inclusion of all of the studies reporting rMS
data, 19/21 rMSs that scored C65 also had SIFT score ¼
0.00 (the remaining two, p.I2401T and p.I2914T, had
SIFT score ¼ 0.01) (DSRI was excluded from this and the
following comparisons because analysis of in-frame dele-
tions is very awkward). In contrast, 15/34 rMSs with
a SIFT score¼ 0.00 had Align-GVGD grades that are distrib-
uted from C0 to C55. When the rMSs with SIFT scores ¼
0.00 were stratiﬁed into those that were also C65 versus
those that were not, the group with SIFT scores ¼ 0.00
and C65 appeared to be associated with a higher OR
than those that were SIFT score ¼ 0.00 but not C65 (ORs
of 5.22 [1.86–20.24] and 0.93 [0.37–2.44], respectively,
with PFET for the difference ¼ 0.011). The difference
between these scoring criteria is made apparent in Figure 2.
Substitutions scored as C65 fell at positions that either are
invariant or have cross-species variation that is limited to
Ile-Leu-Met, and the substitutions were clearly nonconser-
vative with respect to the position at which they fell.
Substitutions that were SIFT¼ 0.00 but not C65were either
relatively conservative substitutions that fell at invariant
positions (speciﬁcally, the standard Grantham difference
is < 65) or nonconservative substitutions that fell at posi-
tions having slightly greater cross-species variation than
the extremely conservative Ile-Leu-Met set, as judged by
their Grantham variations.
Sensitivity
To explore whether any of the individual studies affected
the signiﬁcance or magnitude of our summary OR esti-
mates, we conducted leave-one-out tests of sensitivity
(Table 7) in which each of the ten bona ﬁde case-control
studies was removed in turn (for this analysis, studies 9a
and 9b were considered as separate studies; note also that
there were no signiﬁcant effects attributable to inclusion
or exclusion of single case-only or control-only studies
[data not shown]). Of our four main tests—TþSJ variants,
the whole-gene rMS trend test, the carboxy-third rMS
trend test, and the FATþkinaseþFATC rMS trend test—
the analysis of TþSJ variants proved to be the most sensi-
tive. For this test, 7/10 leave-one-out tests rejected the
null with p < 0.05; two of the remaining had 0.05 % p <
0.10, and one (exclusion of study 5) resulted in p ¼
0.178. The three missense-substitution trend tests were
more robust, with 23/24 leave-one-out tests rejecting the
null with p < 0.05 and the remaining test returning p ¼
0.06. Because of loss of power, removing a relatively large
study could render the pooled result from the remaining
studies nonsigniﬁcant even if there was little or no change
in the OR point estimate. For the TþSJ tests, the leave-
one-out OR point estimates were all between 0.773 and
1.183 of the overall OR point estimate. Exponentiatingican Journal of Human Genetics 85, 427–446, October 9, 2009 437
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the ln(OR) regression coefﬁcients obtained fromanalyses of
the rMSs to convert them toOR space, we found that the re-
sulting exponentiated coefﬁcients were all between 0.953
and 1.453 of their respective complete data analyses.
Finally, analysis of the FATþkinaseþFATC C65 rMS versus
TþSJ comparison revealed that each of the four largest
studies was required in order to obtain p < 0.05. Even for
this analysis, the ratio of the OR estimated for these C65
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Figure 2. ATM Missense Substitutions Graded C65 by Align-
GVGD and/or Scored 0.00 by SIFT
Substitution designations are given over their respective positions
in the ATM alignment. Amino acid symbols are colored to repre-
sent standard Dayhoff groupings.
(A) Substitutions graded as C65; although most of these were
scored 0.00 by SIFT, note that the last two fall at slightly variable
positions and were scored as 0.01 by SIFT. ‘‘y’’ indicates that
p.S2855R is the ﬁrst substitution of the two-amino-acid substitu-
tion p.SV2855_2856RI.
(B) Substitutions scored as 0.00 by SIFT but as C55 or lower by
Align-GVGD.The AmerrMSs from the logistic-regression trend coefﬁcients to the
OR estimated for TþSJ variants stayed above 0.753 of its
value for all of the case-control studies combined.
Discussion
Our meta-analysis of TþSJ variants in ATM is consistent
with an OR for breast cancer of slightly above 2.0 and
a frequency in controls of around 0.5%. Combined with
a recent study of the ‘‘Mennonite’’ ATM founder mutation
p.E1978X,77 there can be little doubt but that this class of
ATM sequence variants confer increased risk of breast
cancer. Our point estimate lies within the 95% conﬁdence
intervals of all of the bona ﬁde case-control studies (data
not shown). Thus, the perceived differences between
studies that have led to controversy over the breast cancer
risk associated with truncating variants in ATM can easily
be attributed to stochastic sampling variation. However,
because case individuals were typically young or had
family history of breast cancer, even our summary ORs
may be inﬂated in comparison to effects in the general
population.
To our knowledge, our meta-analysis of rMSs in ATM is
unique in the biomedical literature. The whole-gene rMS
trend test across noncarriers and the seven grades of
missense substitutions amounts to a test of a null hypoth-
esis with three underlying components: rare missense
substitutions in ATM have no role in breast cancer, the
probability that such ATM missense substitutions are
pathogenic is unrelated to the probability that they are
evolutionarily deleterious, or the Align-GVGD grading of
ATM missense substitutions does not predict evolutionary
ﬁtness. Rejection of this hypothesis with p ¼ 0.0035
implies the alternative: rare missense substitutions in
ATM are associated with breast cancer, the probability
that such substitutions are pathogenic is related to the
probability that they are deleterious, and the Align-
GVGD grading predicts evolutionary ﬁtness. Therefore,
the p value obtained for the overall missense test for trend
ought to be considered a fair measure of the strength of
evidence that at least a subset of rare missense substitu-
tions in ATM confer increased risk of breast cancer. This
being the case, we note that, were ATM a candidate gene,
evidence extracted from the case-control distribution of
rMSs would complement evidence extracted from the
case-control distribution of TþSJ variants to help establish
the gene’s status as a susceptibility gene.Figure 1. Domain Organization of ATM and Case-Control Distribution of Missense Substitutions by Align-GVGD Grade
(A) Distribution of rare C0, C15, and C25 missense substitutions superimposed on the domain organization of ATM. Note that if two
distinct substitutions are located very close to each other, we shifted one by a few amino acids so that the presence of both is visible.
(B) Distribution of rare C35, C45, C55, and C65 missense substitutions. We labeled the C65 missense substitutions falling from Ile1960
until the end of the protein.
(C) Sequence-conservation proﬁle across ATM. The fraction of invariant positions (GV ¼ 0) across the ATM protein multiple sequence
alignment was measured in a 20-residue sliding window. Results were smoothed by inclusion of (1/e 3 sequence invariance) in the ten
residues preceding and trailing each window, then normalized. The analysis was repeated with the use of a conservation criterion of only
conservative substitution or invariance (GV < 65) across species.
Citations correspond to Fernandes et al.,91 Lim et al.,92 Shafman et al.,93 and Khanna et al.94ican Journal of Human Genetics 85, 427–446, October 9, 2009 439
Table 7. Tests of Sensitivity
Test Scenario A
OR [CI] p-Logistic
All case-control studies 2.32 [1.12–4.83] 0.024
Excluding study 1 (Fitzgerald et al.48)a 2.93 [1.31–6.55] 0.009
Excluding study 2 (Teraoka et al.6) 2.41 [1.16–5.02] 0.019
Excluding study 3 (Sommer et al.10) 2.31 [1.11–4.80] 0.025
Excluding study 4 (Thorstenson et al.) 2.14 [1.01–4.53] 0.047
Excluding study 5 (Renwick et al.14) 1.78 [0.77–4.15] 0.178
Excluding study 6 (Hirsch et al.49) 2.53 [1.18–5.40] 0.017
Excluding study 7 (Soukupova et al.50)a 2.01 [0.95–4.24] 0.066
Excluding study 8 (kConFab/Regensburg) 2.04 [0.93–4.46] 0.076
Excluding study 9a (IARC, European) 2.61 [1.17–5.82] 0.019
Excluding study 9b (IARC, East Asian) 2.74 [1.23–6.10] 0.041
Test Scenario B
Coefficientb p-Trend
All case-control studies 0.1318 0.00350
Excluding study 1 (Fitzgerald et al.48)a NA NA
Excluding study 2 (Teraoka et al.6) 0.1237 0.00720
Excluding study 3 (Sommer et al.10) 0.1288 0.00490
Excluding study 4 (Thorstenson et al.) 0.1129 0.01630
Excluding study 5 (Renwick et al.14) 0.0896 0.05950
Excluding study 6 (Hirsch et al.49) 0.1416 0.00220
Excluding study 7 (Soukupova et al.50)a NA NA
Excluding study 8 (kConFab/Regensburg) 0.1151 0.03120
Excluding study 9a (IARC, European) 0.1966 0.00051
Excluding study 9b (IARC, East Asian) 0.1478 0.00180
Test Scenario C
Coefﬁcientb p-Trend
All case-control studies 0.3082 0.00048
Excluding study 1 (Fitzgerald et al.48)a NA NA
Excluding study 2 (Teraoka et al.6) 0.2913 0.00082
Excluding study 3 (Sommer et al.10) 0.2953 0.00064
Excluding study 4 (Thorstenson et al.) 0.2694 0.00190
Excluding study 5 (Renwick et al.14) 0.2664 0.00370
Excluding study 6 (Hirsch et al.49) 0.3206 0.00050
Excluding study 7 (Soukupova et al.50)a NA NA
Excluding study 8 (kConFab/Regensburg) 0.2745 0.00410
Excluding study 9a (IARC, European) 0.5168 0.00170
Excluding study 9b (IARC, East Asian) 0.3202 0.00057
Test Scenario D
Coefﬁcientb p-Trend
All case-control studies 0.4129 0.00220440 The American Journal of Human Genetics 85, 427–446, OctoberIn the whole-gene analysis across the seven grades of
missense substitutions deﬁned by Align-GVGD, there
appears to be only amodest trend fromC0 to C55 followed
by a step function to much higher risk at C65. In the sub-
analysis of the carboxy-third of the protein, the data
from C0 to C55 are more consistent with a trend toward
increasing risk, but there again appears to be a step at
C65. The degree to which the series of ORs resemble
Table 7. Continued
Test Scenario D
Coefﬁcientb p-Trend
Excluding study 1 (Fitzgerald et al.48)a NA NA
Excluding study 2 (Teraoka et al.6) 0.3978 0.00250
Excluding study 3 (Sommer et al.10) 0.3977 0.00230
Excluding study 4 (Thorstenson et al.) 0.3605 0.00480
Excluding study 5 (Renwick et al.14) 0.3673 0.00850
Excluding study 6 (Hirsch et al.49) 0.4305 0.00280
Excluding study 7 (Soukupova et al.50)a NA NA
Excluding study 8 (kConFab/Regensburg) 0.3758 0.00710
Excluding study 9a (IARC, European) 0.7865 0.04762
Excluding study 9b (IARC, East Asian) 0.4207 0.00250
Test Scenario E
p-FETc,d p-FETc,e
All case-control studies 0.0210 0.0187
Excluding study 1 (Fitzgerald et al.48)a 0.0384 NA
Excluding study 2 (Teraoka et al.6) 0.0218 0.0366
Excluding study 3 (Sommer et al.10) 0.0210 0.0187
Excluding study 4 (Thorstenson et al.) 0.0204 0.0337
Excluding study 5 (Renwick et al.14) 0.0357 0.0568
Excluding study 6 (Hirsch et al.49) 0.0226 0.0342
Excluding study 7 (Soukupova et al.50)a 0.0103 NA
Excluding study 8 (kConFab/Regensburg) 0.0413 0.0695
Excluding study 9a (IARC, European) 0.0845 0.0705
Excluding study 9b (IARC, East Asian) 0.0393 0.0662
Bold font is used to indicate leave-one-out analyses resulting in point estimates
or trend coefficients with p> 0.05. Abbreviations are as follows: OR, odds ratio;
CI, confidence interval; NA, not applicable.
Test scenario A: logistic regression ORs and p value for TþSJ.
Test scenario B: trend test on missense substitutions across the whole gene
(excluding carriers of TþSJ variants and adjusting for study).
Test scenario C: trend test on missense substitutions after residue Ile1960
(excluding carriers of TþSJ variants and adjusting for study).
Test scenario D: trend test on missense substitutions in the FATþKinaseþFATC
domains (excluding carriers of TþSJ variants and adjusting for study).
Test scenario E: comparison between C65 rMSs in the FATþKinaseþFATC
domains versus TþSJ variants.
a Study included in tests of TþSJ variants only.
b ln(OR) regression coefficient.
c Fisher’s exact test.
d All of the case-control studies were used.
e After exclusion of studies 1 and 7, which used the PTT test and consequently
had zero sensitivity for detection.9, 2009
a step function rather than a log-linear trend does not
weigh against the validity of the p value obtained from
the test for trend.Moreover, although it might be tempting
to report a p value for C65 versus noncarriers as a main
result, such a p value would be invalid because it involves
post hoc optimization over the observed data.78 If future
analyses of rare missense-substitution case-control data
from this or other susceptibility genes consistently show
that ORs for the grade C65 are disproportionately high in
comparison to the trend across the other grades, then we
canmodify the parameters of the test to better ﬁt the previ-
ously observed data. Within the paradigm of the test for
log-trend, such a change could be incorporated by assign-
ing to the grades C0 to C65 row values that have been
determined from regressions against already published
data.
The two rMS positional analyses that we have con-
ducted, e.g., over the carboxy-third of the protein and
the more restrictive PFAM-deﬁned FATþkinaseþFATC
concatenation, are both subset analyses analogous to those
routinely reported in more conventional molecular epide-
miology studies. Thus, the risk estimates and p values
obtained need to be treated with caution because of the
effects of case and control ascertainment criteria, post
hoc analysis, and hidden multiple testing. Still, the results
obtained lead us to propose two hypotheses: (1) that rMSs
conferring increased risk of breast cancer are more concen-
trated in the last third of the protein than elsewhere and,
more tentatively (2) that a subset of these rMSs actually
confer higher risk of breast cancer than do TþSJ variants
on average. This second hypothesis resembles that
proposed by Gatti et al., who argued that there should be
a class of common dominant-negative missense substitu-
tions in ATM that confer markedly increased risk of breast
cancer but a less severe A-T phenotype.79 We hypothesize
that the relatively high-risk missense substitutions that
we have tentatively identiﬁed, typiﬁed by C65 missense
substitutions falling in the FAT, kinase, and perhaps
FATC domains, are very rare in the general population,
whereas Gatti et al. proposed that they would be more
common. We also note that recent results from the
WECARE study virtually eliminate the possibility that
any of the relatively common ATM missense substitutions
individually confer more than verymodestly increased risk
of breast cancer.80
On the basis of our tests of sensitivity, the hypothesis
that speciﬁc missense substitutions falling in the last
one-third of ATM may confer greater risk of breast cancer
than do TþSJ variants was the least robust of our principal
ﬁndings. Nonetheless, this hypothesis enjoys two lines of
experimental support. First, there is functional assay
evidence that some missense substitutions and in-frame
deletions falling in the FAT and kinase domains are bio-
chemically dominant negative;81–85 this observation is a
prerequisite for the hypothesis. Second, Spring et al. con-
structed mice that carry the three-amino-acid in-frame
deletion p.SRI2556-2558del3, which corresponds to theThe Amerpathogenic human allele DSRI. The allele encodes a moder-
ately stable protein with biochemically dominant-negative
features34,82 and is therefore more like a pathogenic
missense substitution than like a pathogenic protein-trun-
cating variant. The ATMþ/ mice had little increase in
tumor incidence, whereas the DSRI heterozygote mice
had a notable increase in incidence (relative risk ¼ 3.4,
p ¼ 0.004).82 Thus, one could argue that our result is
a human-genetics conﬁrmation of a published mouse-
genetics result.
If the relatively high-risk for FAT, kinase, and perhaps
FATC domain C65 missense substitutions is replicated in
large, population-based studies, the results would pose an
interesting clinical cancer genetics dilemma. One can
immediately recognize that most truncating variants, and
many variants at canonical GT-AG splice-junction dinucle-
otides, damage function and will be pathogenic. But, in
contrast to BRCA1 and BRCA2, such variants in ATM do
not by themselves confer enough risk to achieve clinical
relevance.86 Nonetheless, our statistical inference is that
C65 missense substitutions in these three domains may
confer, on average, greater risk than do TþSJ variants
and may, therefore, have greater clinical relevance to
heterozygous carriers. However, in the absence of further
characterization, missense substitutions are almost always
considered unclassiﬁed variants. Hence, under current
clinical guidelines, carriers of such substitutions would be
counseled only on the basis of their family history, without
modiﬁcation with respect to their ATM genotype.87 If our
hypothesis is conﬁrmed, then it will become important
to complement the bioinformatic and statistical inferences
used here with pedigree-based genetic analysis and vali-
dated functional assays to reclassify a subset of these
missense substitutions as likely or clearly pathogenic.87–89
In doing so, we should keep two points in mind. First,
some evolutionarily conserved residues outside of the
restrictively deﬁned FAT, kinase, and FATC domains may
also harbor clinically relevant missense substitutions.
Second, we should expect heterogeneity of effect among
missense substitutions that fall into speciﬁc Align-GVGD
or SIFT score categories. Aside from the fact that these
programs do not have perfect speciﬁcity, a simple reason
that this should be so is that missense substitutions falling
in this region of ATM can result in proteins that are quite
stable, of intermediate stability, or very unstable.90 Evolu-
tionarily deleterious missense substitutions that result in
very unstable proteins would not be expected to have
dominant-negative effects, whereas those that result in
stable but functionally compromised proteins are more
likely to have dominant-negative effects.
Several limitations should be considered for this study.
Foremost among them is heterogeneity across the studies,
including design (case-control, case-only, control and/or
population sampling only), case-ascertainment criteria,
and sensitivity of the mutation-screening technique
employed. We handled the problem of study design by
basing our primary analyses on the bona ﬁde case-controlican Journal of Human Genetics 85, 427–446, October 9, 2009 441
studies and then adding in data from the case-only and
control-only studies to show that their addition did not
result in any substantial changes. For case-ascertainment
criteria, we excluded studies that restricted breast cancer
cases by treatment response or speciﬁc tumor characteris-
tics in an effort to exclude selection criteria that might
have biased toward (or away from) any speciﬁc genetic
predisposition. An additional source of heterogeneity was
the race and/or ethnicity distribution in the individual
studies. For many of the studies, we know the fraction of
subjects who were members of one or another ethnic
group, but the published data were not usually detailed
enough to allow us to ascribe individual sequence variants
to subjects of speciﬁc ethnicity. Consequently, it was not
possible to do a stratiﬁed analysis. The largest non-North-
west European groups were the African American cases
and controls screened by Hirsch et al.49 and the East Asian
cases and controls screened in the IARC study 9b. For the
logistic regressions, each of these comprised a single study;
consequently, the logistic-regression adjustment for study
acted as a proxy for ethnicity. Finally, the effect of leaving
these studies out is summarized in the tests of sensitivity
presented in Table 7.
The analyses reported here have implications for any
disease in which rare variants, especially missense substitu-
tions of unknown function, are likely to play a role in
susceptibility. These implications will be magniﬁed as
mutation screening of whole transcriptomes becomes
economically feasible. To use the breast cancer analogy,
recognition of high-risk genes, such as BRCA1 and
BRCA2, would be accomplished easily by mutation
screening of a limited number of cases. But recognition
of the intermediate-risk genes, such as ATM, CHEK2, and
PALB2, may be much more challenging. Because controls
carry pathogenic sequence variants in these genes at
substantial frequency, results from case-only mutation
screening would be quite misleading. Moreover, because
about one-half of the observations of rare ATM C25–C65
and TþSJ variants are of variants that occur only once in
> 5000 individuals, mutation screening of a limited series
of subjects followed by genotyping of cases and controls
could miss a substantial fraction of variants of interest—
hence the importance of case-control mutation screening
as a method of addressing the problem of rare variants.
Even so, at the ORs and frequencies that we have reported
(Tables 4 and 6), 1350 of cases and of controls are required
for the ability to detect evidence of risk with 80% power
with the use of a model that combines assessment of rare
missense substitutions with TþSJ variants, 2200 of each
are required for detecting evidence of risk in a rare
missense-substitution-only model, and 3800 of each are
required for a TþSJ-only model. Analysis of rare missense
substitutions along the lines of the strategy described
here provides a gain in power relative to either analyses
focused on TþSJ variants alone or analyses that include
rare missense substitutions via stratiﬁcation on frequency
followed by a test of heterogeneity. However, the gain in442 The American Journal of Human Genetics 85, 427–446, Octobepower offered by bioinformatic grading of missense substi-
tutions followed by a test for trend over the ordered grades
will carry the price of creating properly curated sequence
alignments of appropriate phylogenetic depth. Moreover,
with multiple testing taken into account, the number of
subjects needing to be screened will be daunting, even if
only all of the genes in a particular biochemical pathway
are evaluated.
Supplemental Data
Supplemental Data include two tables and an ATM protein
multiple sequence alignment and can be found with this article
online at http://www.cell.com/AJHG/.
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